Pfizer Inc. (PFE) share price at $24.15 on September 18th, with trailing and forward P/E at 12.78 and 7.74 respectively. Post-COVID revenue normalization saw sales drop to $58 billion in 2023, but forecasted rebound to $64 billion by 2025 with new drug launches in oncology and rare diseases.

Pfizer generates over $18 billion in annual free cash flow, maintains strong balance sheet with $60 billion debt, $80 billion equity, and $15 billion cash equivalents. Offers dividend yield near 6.7%, historically high but supported by consistent cash generation. Technical indicators support medium-term bullish thesis with disciplined entry points and upside targets of $27.50 and $29.

Bullish thesis on Pfizer Inc. remains strong despite 17% stock depreciation post-COVID revenue normalization. High dividend yield, strong pipeline, and attractive valuation. Investing With Purpose emphasizes detailed financials and technical entry points, projecting potential capital appreciation for medium- to long-term investors.

Read more at Yahoo Finance: Pfizer Inc. (PFE): A Bull Case Theory